04.04.26 -- Drug Discovery Online Best Of March

Examining natural mechanisms of cardiac repair in hibernating squirrels has provided insight into biological pathways that could help develop a therapeutic for HFpEF.

By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

We caught up with Ajit Parhi, Ph.D., CSO of TAXIS Pharmaceuticals, to discuss policy, precision science, and AI in battling antimicrobial resistance.

Early collaboration between R&D and manufacturing ensures regulatory readiness and efficiency. Learn how automation and robust panel design enable clinical translation for advanced development.

We are beginning to see a rise in the interest of “orphan drugs." Discover challenges and considerations associated with the expedited development and how to successfully work through them.

Sensitive digital PCR methods enable confident detection of low‑abundance iPSC markers. Gain insight into how these capabilities support more reliable monitoring and quality assessment.